IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

Clinical trial NCT06790706 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06790706
Sponsor: Hospices Civils de Lyon
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Peritoneal Mesothelioma Gestational Trophoblastic Tumor Anaplastic Thyroid Carcinomas Gastroenteropancreatic Neuroendocrine Tumor Carcinoid Tumor Thymic Carcinoma

Start date: 2025-10-01
Primary completion: 2028-11-01
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.